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Human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell
leukemia/lymphoma (ATLL) and several inﬂammatory diseases. Tax, the protein encoded
by HTLV-1, may be responsible for the development of the diseases caused by this virus.
To investigate the pathogenic role of Tax, several transgenic mouse strains expressing Tax
have been developed in recent years. These mice develop various tumors including large
granular lymphocytic leukemia, as well as inﬂammatory diseases such as arthritis. These
results suggest that Tax expression alone is sufﬁcient to cause both malignant neoplastic
diseases and inﬂammatory diseases. However, until recently, there were no tax transgenic
mice that develop T cell leukemia and lymphoma resembling ATLL. The ﬁrst successful
induction of leukemia in T cells was pre-T cell leukemia generated in transgenic mice in
which a mouse lymphocyte-speciﬁc protein tyrosine kinase p56lck (lck )-proximal promoter
was used to express the tax gene in immatureT cells. Subsequently, transgenic mice were
established in which the lck -distal promoter was used to expressTax in matureT cells; these
mice developed mature T cell leukemia and lymphoma that more closely resembled ATLL
than did earlier mouse models.
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INTRODUCTION
Human T cell leukemia virus type 1 (HTLV-1) was the ﬁrst human
retrovirus to be isolated (Poiesz et al., 1980). It is estimated that
10–20 million people worldwide are infected with HTLV-1, which
is endemic in southwestern Japan, the Caribbean Islands, South
America, and Africa. Infection with HTLV-1 can result in an
aggressive malignancy known as adult T cell leukemia/lymphoma
(ATLL) or in inﬂammatory diseases, such as HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP), after a pro-
longed period of latency often lasting between 20 and 50 years
(Watanabe, 1997). The lifetime incidence of ATLL among car-
riers of HTLV-1 was estimated to be 1–5%, whereas that of
HAM/TSP was 0.3–4.0% (Verdonck et al., 2007). The lifetime
incidence of HTLV-1-associated diseases in general, including
ATLL,HAM/TSP, and other inﬂammatory diseases, such as uveitis,
polymyositis, arthropathy, and infective dermatitis, may be close
to 10% (Verdonck et al., 2007). However, the reasons why HTLV-
1-infected individuals develop different types of diseases and the
mechanisms through which HTLV-1 causes these diseases remain
unclear. To address these questions, an appropriate animal model
is required.
HTLV-1 GENOME
The HTLV-1 genome consists of a diploid plus-strand RNA.
Like other retroviruses, the integrated HTLV-1 proviral genome
contains long-terminal-repeat (LTR) regions ﬂanking the genes
encoding the major structural proteins, gag, pol, and env. The
genome also has an extra sequence designated pX. The pX region
has four partially overlapping open reading frames designated I,
II, III, and IV, which encode the proteins p12, p13, and p30, Rex,
andTax, respectively (Grassmann et al., 2005; Matsuoka and Jeang,
2007). Tax and Rex act in combination to regulate HTLV-1 gene
expression and replication in both positive and negative path-
ways (Yoshida, 2005). p12 is thought to facilitate persistent viral
infection (Albrecht et al., 2000). p30 attenuates HTLV-1 transcrip-
tion by suppressing Tax protein synthesis (Nicot et al., 2004). The
role of p13 is currently unclear. The HTLV-1 minus-strand RNA
encodes a basic leucine zipper factor (HBZ) and the protein is
synthesized in an antisense fashion from the 3′ LTR (Larocca et al.,
1989; Gaudray et al., 2002). HBZ inhibits Tax-mediated trans-
activation of viral transcription (Arnold et al., 2006; Lemasson
et al., 2007; Clerc et al., 2008). However, several researchers have
reported that HBZ mRNA, but not HBZ protein, could induce T
cell proliferation and to promote cell survival (Satou et al., 2006;
Arnold et al., 2008). At present, the role of HBZ in HTLV-1 infec-
tion is controversial. More recently, Satou et al. (2011) created hbz
transgenic mice and reported that more than one-third of these
mice developed T cell lymphoma after a long latent period.
The transcription activator protein, Tax, is one of the regula-
tory proteins encoded by the pX region that has been extensively
studied in vitro. Tax is a 40 kDa phosphoprotein that is essential
for both viral replication and cellular transformation (Yoshida,
2001; Jeang et al., 2004). Transactivation of Tax is thought to initi-
ate the processes that lead to ATLL or inﬂammatory diseases (Sun
andYamaoka, 2005; Matsuoka and Jeang, 2007; Currer et al., 2012;
Yamagishi and Watanabe, 2012).
tax TRANSGENIC MICE
One of the best ways to investigate the oncogenic role(s) of tax in
vivo is to generate a transgenic mouse model expressing HTLV-1
Tax (Table 1). The ﬁrst HTLV-1 tax transgenic mice, in which Tax
was expressed under the control of the HTLV-1 LTR, developed
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Table 1 | Representative tax transgenic mouse models.
Promoter Gene Diseases ATLL-like HAM/TSP-like Reference
HTLV-1 LTR tax Thymic involution None None Hinrichs et al. (1987)
Neuroﬁbroma Nerenberg et al. (1987)
Early death
HTLV-1 LTR tax Sjögren-like syndrome
(exocrinopathy)
None None Green et al. (1989)
HTLV-1 LTR env-pX Arthritis None None Iwakura et al. (1991)
HTLV-1 LTR tax Arthritis None None Habu et al. (1999)
CD4 tax Arthritis None None
HTLV-1 LTR tax Skeletal abnormalities None None Ruddle et al. (1993)
Granzyme B tax Granular lymphocytic leukemia Leukemia/lymphoma None Grossman et al. (1995)
Metallothionein tax Arthropathy None None Saggioro et al. (1997)
lck -proximal tax CD4−CD8− pre-T-cell leukemia Leukemia/lymphoma None Hasegawa et al. (2006)
lck -distal tax CD4+, CD8+, and CD4+CD8+
T-cell leukemia
Leukemia/lymphoma Symmetrical paraparesis
of the hind limbs
Ohsugi et al. (2007)
Arthropathy
Histiocytic sarcoma (spinal cord)
thymic involution, neuroﬁbroma, and early death (Hinrichs et al.,
1987; Nerenberg et al., 1987). Studies of these mice indicated that
Tax expression alone was sufﬁcient to induce tumorigenesis in
transgenic mice. Iwakura et al. subsequently reported a very high
incidence of inﬂammatory arthritis in transgenic mice carrying
the HTLV-1 env–pX region (pX transgenic mice) or tax with the
HTLV-1 LTR promoter (Iwakura et al., 1991; Habu et al., 1999).
Arthropathy develops in pX transgenic mice as early as 4 weeks of
age, and inﬂammatory arthropathy was also reported in another
tax transgenic mouse model (Saggioro et al., 1997). These reports
suggest that Tax expression induces inﬂammatory diseases inmice.
Other transgenic mice were reported to develop Sjögren’s-like
syndrome (Green et al., 1989) and skeletal abnormalities (Ruddle
et al., 1993).
However, none of these transgenic mouse models developed
leukemia and lymphoma. The HTLV-1 LTR was used to regulate
tax expression in these models. Other promoters were used in
transgenic constructs to restrict tax expression to the lymphoid
compartment and establish a better model of ATLL-like malig-
nancies. Grossman et al. (1995) used the granzyme B promoter
to drive tax expression in the mature T cell compartment. Those
mice developed large granular lymphocytic leukemia, demonstrat-
ing that Tax expression alone in the lymphocyte compartment is
sufﬁcient for the development of leukemia.
T CELL LEUKEMIA IN tax TRANSGENIC MICE
Tax expression in transgenic mice caused large granular lympho-
cytic leukemia, but none of the transgenic mice developed T cell
leukemia and lymphoma resembling ATLL. Recently, Hasegawa
et al. (2006) established transgenic mice in which tax expression
was restricted to thymocytes by using the lymphocyte-speciﬁc
protein tyrosine kinase p56lck (lck)-proximal promoter. These
mice developed pre-T cell (CD4−CD8−CD44+CD25+) leukemia
and lymphoma. Histological analysis showed diffuse, large-cell
lymphomas involving the spleen, lymphnodes, liver, thymus, bone
marrow, kidney, lung, meninges, and skin. The histopatholog-
ical ﬁndings were identical to those observed in ATLL patients.
The mice were functionally immunocompromised and devel-
oped opportunistic infections, which are also characteristics of
ATLL. The leukemic cells were transplantable to severe combined
immunodeﬁcient mice. These transgenic mice demonstrated that
Tax expression in the lymphocyte compartment is sufﬁcient for
the development of T cell leukemia and lymphoma. One major
difference between these mice and humans with the disease is in
the phenotype of the tumor cells, as the most common phenotype
in ATLL in humans is CD4+ mature T cells (Watanabe et al., 1997;
Matsuoka and Jeang, 2007; Verdonck et al., 2007).
We created a transgenic mouse model of HTLV-1 using the dis-
tal promoter of lck to express tax in mature T cells (Ohsugi et al.,
2007). The expression of the lck gene is regulated by two distinct
promoter elements, a proximal and a distal promoter (Voronova
et al., 1987; Perlmutter et al., 1988; Takadera et al., 1989). The
lck-proximal promoter is most active in immature thymocytes,
whereas the activity of the distal promoter is higher in mature
thymocytes and peripheral T lymphocytes (Reynolds et al., 1990;
Wildin et al., 1991; Allen et al., 1992). Tax mRNA expression in
various organs of the transgenic mice was examined by quantita-
tive real-time RT-PCR. The thymus and spleen strongly expressed
Tax mRNA. Over 2 years, 28.1% of the tax transgenic mice devel-
oped mature T cell leukemia/lymphoma compared with just 1%
of non-transgenic littermates.
PHENOTYPE OF T CELL LEUKEMIA IN tax TRANSGENIC MICE
The ﬁnal cell speciﬁcation to the T cell lineage takes place
within the thymus. An overview of thymic T cell development is
illustrated in Figure 1, and involves a series of distinct stages that
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FIGURE 1 |T cell development in the thymus. Hematopoietic stem
cells arise in the bone marrow and migrate to the thymus. Early committed
T cells do not express CD4 or CD8, and are referred to as double-negative
(DN; i.e., CD4− or CD8−) thymocytes. DN thymocytes can be further
subdivided into four stages of differentiation (DN1, CD44+CD25−; DN2,
CD44+CD25+; DN3, CD44−CD25+; and DN4, CD44−CD25−). At the
DN3 stage, DN cells express a pre-T cell receptor (TCR) and its surface
expression triggers the upregulation of CD4 and CD8 expression on
the cell surface, and progression to the CD4+CD8+ double-positive (DP)
stage. DP cells then mature into either CD4+ or CD8+ single-positive
(SP) T cells. lck -proximal tax transgenic mice develop pre-T-cell leukemia
originating from DN2/3 stage cells, whereas lck -distal tax transgenic mice
develop mature leukemia originating after the progression to DP stage
cells.
can be deﬁned by the expression of cell-surface markers. Early
T cells are CD4−CD8− double-negative (DN) and can be further
subdivided into DN1 (CD44+CD25−), DN2 (CD44+CD25+),
DN3 (CD44−CD25+), and DN4 (CD44−CD25−) stages based on
their expression of CD25 and CD44 (Koch and Radtke, 2011).
The productive rearrangement of the T cell receptor (TCR) β
chain locus occurs during the DN3 to DN4 transition, and leads
to the expression of the pre-TCR. Only cells expressing func-
tional pre-TCR proliferate and differentiate into CD4+CD8+
double-positive (DP) cells. However, most DP cells die through
negative selection or neglect because their TCRs have too high
or too low afﬁnity for peptide–major histocompatibility com-
plex molecule complexes. The cells that mature successfully
migrate to theperiphery as functionalCD4+CD8− orCD4−CD8+
single-positive T cells.
The phenotype of T cell leukemia in lck-proximal tax trans-
genic mice was CD4−CD8−, but CD44+, CD25+, and CD117−
(also known as c-kit−; Hasegawa et al., 2006). These results suggest
that the malignant leukemic cells were derived from DN2/3 stage
cells in the thymus. Transgenes controlled by the lck-proximal
promoter are expressed very early in T cell development and can
be detected in DN1 cells, although their expression in the early
progenitors is not homogeneous until the DN3/4 stage (Clev-
erley et al., 1999; Buckland et al., 2000). Various studies have
suggested that the Lck tyrosine kinase plays an important role
in thymocyte development as a signaling molecule downstream
from pre-TCR (Mombaerts et al., 1994; Wallace et al., 1995; van
Oers et al., 1996; Fehling et al., 1997), while pre-TCR was ﬁrst
detected in the CD44−CD25+ DN3 subset (Saint-Ruf et al., 1994;
Bruno et al., 1995). A green ﬂuorescent protein (GFP) transgenic
mouse was created in which gfp expression was under the control
of the proximal promoter of lck, and the earliest GFP-positive cells
were found among the CD44+CD25− DN1 stage cells (Shimizu
et al., 2001). Interestingly, pre-T cell leukemia in lck-proximal tax
transgenic mice was probably derived from DN2/3 stage cells, even
though the lck-proximal promoter is active in DN1–DN4 stage
cells.
The phenotype of T cell leukemia in lck-distal tax transgenic
micedisplayedCD4+, CD8+, orCD4+CD8+ (DP)Tcells. Overall,
60% of the leukemic cells were CD8+CD25− T cells, 25% were
CD4+CD25− T cells, and 15% were CD4+CD8+ T cells (Ohsugi
et al., 2007). As the Tax expression level did not vary in these
cell populations, it remains unclear why CD8+ T cells comprised
approximately 60% of the total mature T cell leukemia cells in the
lck-distal tax transgenic mice.
TAX-RELATED DISEASES IN tax TRANSGENIC MICE
ARTHROPATHY
tax transgenic mice develop an inﬂammatory arthropathy
(Iwakura et al., 1991; Saggioro et al., 1997) that is pathologically
similar to human rheumatoid arthritis and to mouse models of
rheumatoid arthritis, with synovial proliferation and the expres-
sion of rheumatoid factor (Lee and Weinblatt, 2001; Luross and
Williams, 2001; Firestein, 2003). By 24 months of age, our estab-
lished lck-distal tax transgenic mice without leukemia developed
severe arthropathy, with a cumulative incidence of 22.8% (Ohsugi
and Kumasaka, 2011), but no arthropathic mouse was reported
among the lck-proximal tax transgenic mice. The lck-distal tax
transgenic mice with arthropathy differ in several aspects from
other transgenic mice. They develop arthropathy after a prolonged
latency period of at least 9 months, whereas the arthropathy that
develops in the pX transgenic mice occurs as early as 4 weeks
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of age. At 3 months of age, 60% (BALB/c background), 25%
(C3H/He background), and 0% (C57BL/6 background) of pX
transgenic mice displayed arthropathy (Iwakura et al., 1998). The
genetic background of our established lck-distal tax transgenic
mice was the F1 generation of a BDF1 (DBA/2 × C57BL/6) cross
with C57BL/6. We attempted to generate lck-distal tax trans-
genic mice with the BALB/c background (backcross generation
8: N8), but did not observe a high incidence of arthropathy by
24 months of age. The expression of the cytokines interleukin-
1β (IL-1β), IL-6, and macrophage migration inhibitory factor
(MIF) was markedly enhanced in the joints of the lck-distal tax
transgenic mice, but the expression of tumor necrosis factor-α
(TNF-α) was not elevated. Ashino et al. (2007) also found that
serum IL-1β and IL-6 concentrations were signiﬁcantly higher
in pX transgenic mice than those in non-transgenic or non-
arthritic pX transgenic mice. Consistent with our arthropathic
mice, their serum TNF-α concentrations were low, with no sig-
niﬁcant differences between the groups (Ashino et al., 2007). IL-6
is a key proinﬂammatory cytokine that is abundant in the syn-
ovium and synovial tissues of patients with rheumatoid arthritis
(Okamoto et al., 1997). Taken together, these data suggest that
proinﬂammatory cytokines, other than TNF-α, are important in
the development of the inﬂammatory arthropathy associated with
Tax expression.
HAM/TSP-LIKE DISEASE
Eight out of 297 lck-distal tax transgenic mice developed
HAM/TSP-like disease with symmetrical paraparesis of the hind
limbs, whereas these symptoms were absent in their non-
transgenic littermates and in other mouse strains at our animal
facilities (Ohsugi et al., in press). The tax transgenic mice with
HAM/TSP-like disease had spinal cord lesions in the lumbar
vertebrae that were caused by the inﬁltration of bone marrow-
derived histiocytic sarcoma cells. MicewithHAM/TSP-like disease
also displayed abnormal expression of cytokines and chemokines,
including TNF-α and IL-6. Constitutive exposure to high levels
of proinﬂammatory cytokines is thought to be protumorigenic
(Balkwill, 2009; Grivennikov et al., 2009). Therefore, we spec-
ulated that tax-expressing T cells stimulate the proliferation
of histiocytic cells in bone marrow through the activities of
cytokines or chemokines. The transformed histiocytic cells may
then predominantly invade the lumbar spinal cord (Ohsugi et al.,
in press).
To my knowledge, there have been no reports of spontaneous
symmetrical paraparesis caused by histiocytic sarcoma in mice.
However, the lesions in patients with HAM/TSP show marked T
cell inﬁltration, and the disease is associated with an inﬂamma-
tory state (Sakai et al., 2001; Kubota et al., 2002; Goon et al., 2003;
Muraro et al., 2003). Therefore, it is important to note that the
etiology of HAM/TSP-like disease in lck-distal tax transgenic mice
differs substantially from that of HAM/TSP in humans. Never-
theless, the present results indicate that the relationship between
HTLV-1 infection and histiocytic disorders should be the focus of
future studies. In particular, those studies should examinewhether
the cytokines and chemokines secreted from HTLV-1-infected T
cells induce the growth or oncogenic transformation of histiocytic
cells in humans. A recent paper proposed that, in a murine model
of multiple sclerosis, there is a gateway through which immune
cells can enter the central nervous system (Arima et al., 2012). The
authors described an entry site by the dorsal blood vessels of the
ﬁfth lumbar cord through which immune cells can enter the cen-
tral nervous system. Histiocytic sarcoma grew predominantly in
the spinal cord of the ﬁfth to sixth lumbar vertebrae in HAM/TSP-
like mice. Further studies are required to conﬁrm that histiocytic
sarcoma cells can access the central nervous system via the spinal
cord at the ﬁfth lumbar vertebra. Such studies may clarify the
mechanisms underlying the movement of Tax-positive T cells into
the central nervous system in humans with HAM/TSP.
CONCLUSION
Several strains of HTLV-1 tax transgenic mice have been devel-
oped over recent years. Studies in these mice have shown that
Tax expression alone is sufﬁcient to cause both malignant neo-
plastic diseases, including T cell leukemia and lymphoma, and
inﬂammatory diseases, such as arthropathy. These mice will be
widely used to study the pathogenesis of HTLV-1 and to evaluate
new anticancer and anti-inﬂammatory agents for HTLV-1-related
diseases. However, until now, none of the tax transgenic mice
developed HAM/TSP-like disease, a systemic immune-mediated
inﬂammatory disease that resembles the disease in humans. Fur-
ther studies are required to establish a transgenic mouse model of
HAM/TSP with the selection of appropriate promoters.
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